Initial results from CRISPR/Cas9-mediated gene editing strategies are encouraging for the development of future treatments for DMD, but further studies are needed to enhance dystrophin production bodywide, as will be needed to treat or prevent dystrophy in patients37, 38. This evidence concerns the gene DMD and Duchenne muscular dystrophy.